Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Alexis Ogdie¹, Sofia Pedro ² and Kaleb Michaud ³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…
Abstract Number: 924 • 2019 ACR/ARP Annual Meeting
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance
Background/Purpose: We recently reported that highly-sensitive cardiac troponin-I (hs-cTnI) associates with occult coronary atherosclerosis burden and cardiovascular event (CVE) risk in rheumatoid arthritis (RA). We…
Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Maria Schletzbaum¹, Xing Wang ¹, Robert Greenlee ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Marshfield Clinic Research Institute, Marshfield, WI
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 1358 • 2019 ACR/ARP Annual Meeting
Defining Minimal Clinically Important Changes for the Patient Activity Scale-II
Joshua Baker¹, Patricia Katz ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²University of California, San Francisco, san francisco, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Patient Activity Scale (PAS)-II is an accepted disease activity measure used in the care of patients with rheumatoid arthritis (RA). A clinically important…
Abstract Number: 1386 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Leslie Harrold¹, Ying Shan ², Sabrina Rebello ², Lin Guo ², Sean Connolly ³, Joe Zhuo ³, Sheila Kelly ³ and Thomas Lehman ³, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: In a US national observational study conducted in a clinical practice setting, patients who were positive (+) for anti-cyclic citrullinated peptide (CCP) antibodies at…
Abstract Number: 1418 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Rafat Faraawi ², Louis Bessette ³, Andrew Chow ⁴, Jodie Reis ⁵, Keltie Anderson ⁵, Emmanouil Rampakakis ⁶, Meagan Rachich ⁷, Odalis Asin-Milan ⁷, Allen Lehman ⁷ and Francois Nantel⁷, ¹Memorial University, Newfoundland, NL, Canada, ²McMaster University, Hamilton, ON, Canada, ³Laval University, Laval, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶JSS Medical Research, Montreal, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled rheumatoid arthritis (RA) patients treated with either subcutaneous golimumab (GLM-SC)…
Abstract Number: 1801 • 2019 ACR/ARP Annual Meeting
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Mahesh Kambhampati ², Francis Lobo ³ and Allison Petrilla ², ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The risk and cost of infection-related hospitalizations in tumor necrosis factor inhibitors (TNFi)-experienced patients with rheumatoid arthritis (RA) receiving subsequent targeted disease-modifying antirheumatic drug…
Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
Abstract Number: 2061 • 2019 ACR/ARP Annual Meeting
Association of Periodontitis with Rheumatological Disorders: NHANES III Analysis
Vivekanand Tiwari¹, Lawrence Brent ¹, Jasim Albandar ², Chinhua Hsiao ² and Shikha Shah ³, ¹Temple University, Philadelphia, PA, ²Kornberg School of Dentistry, Temple University, Philadelphia, PA, ³Levy Center for Oral Health Research, Philadelphia, PA
Background/Purpose: The association between periodontal diseases, smoking, and some systemic diseases such as diabetes mellitusis is well established. Periodontitis and rheumatological disorders share common immunological features and…
Abstract Number: 2253 • 2019 ACR/ARP Annual Meeting
Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
Patrick Webster¹, Nicole Wilson ², Christina Payne ¹, Kelly Shields ³ and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Medicine Institute Research, Bioinformatics, Pittsburgh, PA, ³Highmark Data Science, Pittsburgh
Background/Purpose: The 2015 American College of Rheumatology (ACR) and 2013 European League Against Rheumatology (EULAR) guidelines for management of rheumatoid arthritis (RA) conditionally recommend consideration…
Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2331 • 2019 ACR/ARP Annual Meeting
Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry
Sicong Huang¹, Xintong He ¹, Tracy J. Doyle ², Alessandra Zaccardelli ¹, Allison Marshall ¹, H. Maura Friedlander ³, Rachel Blaustein ³, Elisabeth Smith ³, Christine Iannaccone ¹, Taysir Mahmoud ³, Michael Weinblatt ¹, Paul Dellaripa ¹, Nancy Shadick ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston
Background/Purpose: Pulmonary involvement in rheumatoid arthritis (RA), such as bronchiectasis, bronchiolitis, pleuritis, or interstitial lung disease (ILD), is associated with high morbidity and mortality. Pulmonary…
Abstract Number: 2355 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Thao Nguyen¹, Ingrid Hokstad ², Gia Deyab ³, Tom Eirik Mollnes ⁴, Stefan Agewall ⁴, Morten Fagerland ⁴, Gro Eilertsen ⁵, Mark Feinberg ⁶, Knut Mikkelsen ², Øystein Førre ⁴ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ³Innlandet Hospital Trust, Bærum, Akershus, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵The Artic University of Norway, Tromsø, Norway, ⁶Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Inflammation and immune dysregulation appear to significantly contribute to increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The complement system is a…
Abstract Number: 2378 • 2019 ACR/ARP Annual Meeting
Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
Naureen Kabani¹, Joshy Pathiparampil ², Madina Abduraimova ², Latoya Freeman-Beman ², Sima Terebelo ¹, Abida Hasan ¹, Christon Grant ¹, James Salgado ¹, Manjeet Bhamra ¹, Tracian James-Goulbourne ¹, Khabbab Amin ¹, Yamen Homsi ³ and Isabel McFarlane ², ¹SUNY Downstate Medical Center, Brooklyn, ²SUNY Downstate Medical Center, Brooklyn, NY, ³NYU Langone Medical Center, Brooklyn, NY
Background/Purpose: Rhupus is the overlap of SLE and RA. While a few studies have been conducted among Rhupus patients, no studies have focused on Black…

« Previous Page
1
…
4
5
6
7
8
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].